Orthofuse raises fresh capital for custom 3D‑printed implants
UK medtech startup Orthofuse has secured a £2.2 million funding round to accelerate the development of its surgeon‑adjustable, 3D‑printed orthopaedic implants. The company is targeting a new generation of personalised joint and bone replacements that can be fine‑tuned in the operating room, rather than relying on a limited catalogue of fixed‑size components.
Backed by a mix of venture investors and sector‑focused angels, the new capital will support regulatory work, product refinement and early clinical deployments across leading UK hospitals. The round underscores growing investor confidence in 3D printing and patient‑specific implants as the next wave of innovation in orthopaedic surgery.
A new approach to orthopaedic personalisation
Orthofuse uses advanced additive manufacturing techniques and pre‑operative imaging data to produce implants that closely match each patient’s anatomy. Unlike traditional implants, which are supplied in standardised sizes, Orthofuse’s designs allow surgeons to make last‑minute adjustments to fit and alignment during surgery.
The company’s platform integrates pre‑surgical planning software with proprietary implant materials and surface structures that promote bone integration. By enabling surgeons to tweak key parameters in real time, Orthofuse aims to reduce revision surgeries, shorten operating times and improve long‑term joint performance.
Positioning within the global medtech landscape
The funding comes as health systems worldwide face rising demand for joint replacements, driven by ageing populations and increased rates of sports and lifestyle injuries. Investors are betting that highly tailored solutions will help hospitals deliver better outcomes while managing pressure on surgical capacity.
With this £2.2 million injection, Orthofuse plans to expand its engineering team, deepen collaborations with orthopaedic surgeons and advance its pipeline of knee, hip and trauma implants. If successful, the company could help shift the market away from one‑size‑fits‑all devices toward a new standard of personalised medtech built around 3D‑printed implants and surgeon‑controlled customisation.